See more : Daikaffil Chemicals India Limited (DAIKAFFI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Graf Acquisition Corp. IV (GFOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Graf Acquisition Corp. IV, a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Waste Connections, Inc. (WCN) Income Statement Analysis – Financial Results
- Housing and Urban Development Corporation Limited (HUDCO.BO) Income Statement Analysis – Financial Results
- Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) Income Statement Analysis – Financial Results
- Alice Queen Limited (AQX.AX) Income Statement Analysis – Financial Results
- Anebulo Pharmaceuticals, Inc. (ANEB) Income Statement Analysis – Financial Results
Graf Acquisition Corp. IV (GFOR)
About Graf Acquisition Corp. IV
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in The Woodlands, Texas.
Unable to fetch income statement for: GFOR
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
THE WOODLANDS, Texas , Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, without conducting any business, the special meeting of its...
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
THE WOODLANDS, Texas , Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, without conducting any business, the special meeting of its...
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
THE WOODLANDS, Texas , Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, without conducting any business, the special meeting of its...
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be...
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced the...
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR) (“Graf”), announced today that it has been informed that it currently has received stockholder votes from more than 65% of its stockholders to approve the Extension to September 29, 2023. Graf...
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
THE WOODLANDS, Texas & SANTA ANA, Calif.--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR) (“Graf”), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (“NKGen Biotech”), a biotechnology company focused on harnessing the...
Graf Acquisition Corp. IV Withdraws Extension Proposal
THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the “Company”) today announced that it is withdrawing from the ballot for its special meeting of stockholders to be held on December 21, 2022 (the “Special Meeting”) the...
Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
Source: https://incomestatements.info
Category: Stock Reports